Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 59

1.

Determination of Antibacterial and Technological Properties of Vaginal Lactobacilli for Their Potential Application in Dairy Products.

Siroli L, Patrignani F, Serrazanetti DI, Parolin C, Ñahui Palomino RA, Vitali B, Lanciotti R.

Front Microbiol. 2017 Feb 7;8:166. doi: 10.3389/fmicb.2017.00166.

2.

Novel approaches for the taxonomic and metabolic characterization of lactobacilli: Integration of 16S rRNA gene sequencing with MALDI-TOF MS and 1H-NMR.

Foschi C, Laghi L, Parolin C, Giordani B, Compri M, Cevenini R, Marangoni A, Vitali B.

PLoS One. 2017 Feb 16;12(2):e0172483. doi: 10.1371/journal.pone.0172483.

3.

Spanish Broom (Spartium junceum L.) fibers impregnated with vancomycin-loaded chitosan nanoparticles as new antibacterial wound dressing: Preparation, characterization and antibacterial activity.

Cerchiara T, Abruzzo A, Ñahui Palomino RA, Vitali B, De Rose R, Chidichimo G, Ceseracciu L, Athanassiou A, Saladini B, Dalena F, Bigucci F, Luppi B.

Eur J Pharm Sci. 2017 Mar 1;99:105-112. doi: 10.1016/j.ejps.2016.11.028.

PMID:
27931851
4.

Lactobacillus crispatus inhibits the infectivity of Chlamydia trachomatis elementary bodies, in vitro study.

Nardini P, Ñahui Palomino RA, Parolin C, Laghi L, Foschi C, Cevenini R, Vitali B, Marangoni A.

Sci Rep. 2016 Jun 29;6:29024. doi: 10.1038/srep29024.

5.

Microparticles based on chitosan/carboxymethylcellulose polyelectrolyte complexes for colon delivery of vancomycin.

Cerchiara T, Abruzzo A, Parolin C, Vitali B, Bigucci F, Gallucci MC, Nicoletta FP, Luppi B.

Carbohydr Polym. 2016 Jun 5;143:124-30. doi: 10.1016/j.carbpol.2016.02.020.

PMID:
27083351
6.

Association of Lactobacillus crispatus with fructo-oligosaccharides and ascorbic acid in hydroxypropyl methylcellulose vaginal insert.

Vitali B, Abruzzo A, Parolin C, Palomino RA, Dalena F, Bigucci F, Cerchiara T, Luppi B.

Carbohydr Polym. 2016 Jan 20;136:1161-9. doi: 10.1016/j.carbpol.2015.10.035.

PMID:
26572459
7.

Vaginal microbiome and metabolome highlight specific signatures of bacterial vaginosis.

Vitali B, Cruciani F, Picone G, Parolin C, Donders G, Laghi L.

Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2367-76. doi: 10.1007/s10096-015-2490-y.

PMID:
26385347
8.

Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity.

Parolin C, Marangoni A, Laghi L, Foschi C, Ñahui Palomino RA, Calonghi N, Cevenini R, Vitali B.

PLoS One. 2015 Jun 22;10(6):e0131220. doi: 10.1371/journal.pone.0131220.

9.

Chitosan based micro- and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods.

Cerchiara T, Abruzzo A, di Cagno M, Bigucci F, Bauer-Brandl A, Parolin C, Vitali B, Gallucci MC, Luppi B.

Eur J Pharm Biopharm. 2015 May;92:112-9. doi: 10.1016/j.ejpb.2015.03.004.

PMID:
25769679
10.

Development of a microarray-based tool to characterize vaginal bacterial fluctuations and application to a novel antibiotic treatment for bacterial vaginosis.

Cruciani F, Biagi E, Severgnini M, Consolandi C, Calanni F, Donders G, Brigidi P, Vitali B.

Antimicrob Agents Chemother. 2015 May;59(5):2825-34. doi: 10.1128/AAC.00225-15.

11.

Vaginal inserts based on chitosan and carboxymethylcellulose complexes for local delivery of chlorhexidine: preparation, characterization and antimicrobial activity.

Bigucci F, Abruzzo A, Vitali B, Saladini B, Cerchiara T, Gallucci MC, Luppi B.

Int J Pharm. 2015 Jan 30;478(2):456-63. doi: 10.1016/j.ijpharm.2014.12.008.

PMID:
25490184
12.

Rifaximin modulates the vaginal microbiome and metabolome in women affected by bacterial vaginosis.

Laghi L, Picone G, Cruciani F, Brigidi P, Calanni F, Donders G, Capozzi F, Vitali B.

Antimicrob Agents Chemother. 2014 Jun;58(6):3411-20. doi: 10.1128/AAC.02469-14.

13.

Bacterial vaginosis: a review on clinical trials with probiotics.

Mastromarino P, Vitali B, Mosca L.

New Microbiol. 2013 Jul;36(3):229-38. Review.

14.

Proteome profiles of vaginal fluids from women affected by bacterial vaginosis and healthy controls: outcomes of rifaximin treatment.

Cruciani F, Wasinger V, Turroni S, Calanni F, Donders G, Brigidi P, Vitali B.

J Antimicrob Chemother. 2013 Nov;68(11):2648-59. doi: 10.1093/jac/dkt244.

PMID:
23798671
15.

Chitosan/alginate complexes for vaginal delivery of chlorhexidine digluconate.

Abruzzo A, Bigucci F, Cerchiara T, Saladini B, Gallucci MC, Cruciani F, Vitali B, Luppi B.

Carbohydr Polym. 2013 Jan 16;91(2):651-8. doi: 10.1016/j.carbpol.2012.08.074.

PMID:
23121960
16.

Dietary supplementation with probiotics during late pregnancy: outcome on vaginal microbiota and cytokine secretion.

Vitali B, Cruciani F, Baldassarre ME, Capursi T, Spisni E, Valerii MC, Candela M, Turroni S, Brigidi P.

BMC Microbiol. 2012 Oct 18;12:236. doi: 10.1186/1471-2180-12-236.

17.
18.

Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota.

Cruciani F, Brigidi P, Calanni F, Lauro V, Tacchi R, Donders G, Peters K, Guaschino S, Vitali B.

Antimicrob Agents Chemother. 2012 Aug;56(8):4062-70. doi: 10.1128/AAC.00061-12.

19.

An in vitro evaluation of the effect of probiotics and prebiotics on the metabolic profile of human microbiota.

Vitali B, Ndagijimana M, Maccaferri S, Biagi E, Guerzoni ME, Brigidi P.

Anaerobe. 2012 Aug;18(4):386-91. doi: 10.1016/j.anaerobe.2012.04.014.

PMID:
22579985
20.

Novel probiotic candidates for humans isolated from raw fruits and vegetables.

Vitali B, Minervini G, Rizzello CG, Spisni E, Maccaferri S, Brigidi P, Gobbetti M, Di Cagno R.

Food Microbiol. 2012 Aug;31(1):116-25. doi: 10.1016/j.fm.2011.12.027.

PMID:
22475949
Items per page

Supplemental Content

Loading ...
Support Center